Low Concentration of Rapamycin Inhibits Hemangioma Endothelial Cell Proliferation, Migration, and Vascular Tumor Formation in Mice  by Zheng, Ningning et al.
Current Therapeutic Research 76 (2014) 99–103Contents lists available at ScienceDirectCurrent Therapeutic Researchhttp://d
0011-39
n Add
siology,
City, Ch
E-mjournal homepage: www.elsevier.com/locate/cuthreLow Concentration of Rapamycin Inhibits Hemangioma Endothelial
Cell Proliferation, Migration, and Vascular Tumor Formation in Mice
Ningning Zheng, PhD1,n, Xudong Ding, MD2, Rabita Jahan3
1 Department of Pathophysiology, China Medical University, Shenyang, China
2 Department of Anesthesiology, Shengjing Hospital of China Medical University, Shenyang, China
3 International Education School, China Medical University, Shenyang, Chinaa r t i c l e i n f o
Article history:
Accepted 16 September 2014
Background: Vascular endothelial cell excessive proliferation is the main biological behavior of heman-
gioma. Rapamycin regulates the growth of endothelial cells by inhibiting mammalian target of rapamycinKey words:
Hemangioma
protein kinase B
mechanistic target of rapamycin
rapamycinx.doi.org/10.1016/j.curtheres.2014.09.004
3X/& 2014. The Authors. Published by Elsevier
ress correspondence to: Ningning Zheng, Ph
China Medical University, No. 92, N Second R
ina 110001.
ail address: nnzheng@mail.cmu.edu.cn (N. Zha b s t r a c t
(mTOR). Thus hemangioma accompanied by excessive mTOR activation should be sensitive to rapamycin.
We aimed to illustrate the effect of low-concentration rapamycin on hemangioma and provide a safe and
effective drug therapy.
Methods: Mouse hemangioendothelioma endothelial cells and Nu/Nu mice were used. Rapamycin was
applied in a concentration from 1 nM to 20 nM. WST-1 cell proliferation and transwell migration assays
were used to analyze vascular tumor proliferation and migration in vitro. Xenograft mouse models were
used to test vascular tumor growth in vivo.
Results: Low-concentration rapamycin (1 nM) inhibited hemangioendothelioma endothelial cell prolif-
eration and migration in vitro and vascular tumor growth in vivo. The mechanism was decreased
activation of the protein kinase B/mTOR/S6 ribosomal protein (S6) signaling pathway.
Conclusions: Rapamycin used in vitro was analogous to low serum concentration rapamycin (7–16 nM)
and also signiﬁcantly inhibited the growth of hemangioma. These results demonstrate a low-toxic drug
therapy for hemangioma and encourage continued development of rapamycin and its analogs for use in
vascular tumor therapy.
& 2014. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
A hemangioma is a congenital anomaly composed of a mass of
blood vessels that resemble a tumor with a variety of clinical
manifestations.1–3 So far, the cellular and biomolecular mecha-
nisms of hemangioma formation are unclear. The treatment of
hemangioma mainly involves hormone therapy, chemical therapy,
laser ablation, and surgical resection.4 These methods lead to side
effects of varying degrees, especially in children. Rapamycin is an
antifungal, antineoplastic, and antibacterial macrolide drug. By
binding to the cytosolic protein FK-binding protein 12, it inhibits
the function of the mammalian target of rapamycin (mTOR), which
is a speciﬁc cell regulatory protein responsible for eukaryotic cell
and tumor cell growth. Rapamycin not only shows a strong effect
of immune suppression, but also prevents postangioplastyInc. This is an open access article u
D, Department of Pathophy-
d, Heping District, Shenyang
eng).coronary artery restenosis. It can also be used in a wide range of
antineoplastic therapies.5–7 As a speciﬁc mTOR inhibitor, it has
been used as a chemical activator in autophagy research both
in vitro and in vivo.8 We aimed to illustrate the effect of low-
concentration rapamycin on the growth and proliferation of
hemangioma, and provide a safe and effective drug therapy.Methods
All the animal work described in this article was carried out in
accordance with EC Directive 86/609/EEC for animal experiments.
Cell line and culture maintenance
Mouse hemangioendothelioma endothelial (EOMA) cells9 were
used. EOMA cells were adapted for growth in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) with 4.5 g/L glucose supplemented with
10% fetal bovine serum (FBS) and antibiotics. Rapamycin was
diluted into 2.5 mg/mL in dimethylsulfoxide and stored at
201C. The work concentrations of rapamycin were diluted innder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0 1 5 10
*
*
*
*
Full DMEM+Rapamycin(nM)
20serum
free
A
bs
or
pt
io
n(
45
0n
m
)
Figure 1. Low concentration of rapamycin treatment affected hemangioendothe-
lioma endothelial (EOMA) cell proliferation (n ¼ 4 in each group). Rapamycin (1–
20 nM) all inhibited EOMA cell proliferation compared with serum control (P o
0.05). DMEM ¼ Dulbecco’s modiﬁed Eagle’s medium.
N. Zheng et al. / Current Therapeutic Research 76 (2014) 99–103100DMEM (from 1–20 nM). EOMA cells of serum-starved were
cultivated in DMEM with 1% FBS for 18 hours. EOMA cells of
serum group were cultured in a full DMEM medium. Rapamycin
was applied to EOMA cells overnight in a gradually increasing
concentration (from 1–20 nM).
Immunoblotting
A standardized protocol was used to analyze the phosphoryla-
tion of the protein kinase B (AKT)/mTOR signaling pathway in
EOMA cells treated with rapamycin. EOMA cells cultured in a 60-
mm plate were treated with 10 nM rapamycin. After 48 hours,
scraped cell lysates were harvested. Western blot analysis was
performed in triplicate as described elsewhere.10 All antibodies,
including phospho-AKT (Ser473), phospho-mTOR, phospho-
glycogen synthase kinase-3 beta (GSK3β), and phospho-S6
Ribosomal Protein (S6) were purchased from Cell Signaling Tech-
nology (Danvers, MA, United States). α-Tubulin was purchased
from Calbiochem (San Diego, CA, United States).
WST-1 cell proliferation assay
EOMA cells (1103 per well) were plated in a 96-well plate in
complete medium. The mediumwas replaced the following day with
fresh medium with and without rapamycin. EOMA cells were then
cultured for 48 hours. Proliferation was assayed using a WST-1 assay.
WST-1 reagent (10 μL) was added to each well and EOMA cells were
incubated again for another 4 hours. The absorbency of the samples
was measured against a background control as blank at 450 nm using
a microplate reader according to the manufacturer’s protocol.
Cell migration assay
Transwell cell inserts are from Corning (Tewksbury, MA, United
States) with 8-μm pores were used. Growth factor-reduced matri-
gel (100 μL) was ﬁrst diluted to 1 mg/mL by serum free cold DMEM
and then added into the upper chamber of a Transwell support and
incubated for 4 hours for gelling at 371C and 5% carbon dioxide.
EOMA cells (100 μL) at o50% conﬂuence were pretreated with and
without rapamycin in normal growth medium for up to 48 hours
before seeding into the cell inserts. The lower chamber was ﬁlled
with medium containing a chemoattractant (ie, vascular endothe-
lial growth factor [VEGF] 10 ng/mL). The cells were then incubated
for 24 hours. Unmigrated EOMA cells were scraped from the upper
side of the inserts, and the migrated EOMA cells were stained with
Diff-Quick Stain kit was from IHCWorld(Woodstock, MD, United
States) and counted under an inverted microscope. The data were
expressed as the average of 4 high-power ﬁelds of triplicate
samples after subtraction of the average of cells migrating toward
medium without chemoattractant.
Animals and tumor growth
Four- to 6-week old female Nu/Nu mice were used in our
experiments. Vascular tumor model was established by subcutane-
ous injection. EOMA cells were injected subcutaneously in the ﬂank
of mice (2105 cells per site, 2 sites per mouse, 5 mice per group).
Rapamycin or vehicle was injected daily intraperitoneally. The mice
were under close observation daily to monitor their general condition
and measure the tumor size with a caliper. The mice were then
sacriﬁced after 2 weeks of treatment with rapamycin.
Statistical analysis
All results are expressed as mean (SD). The statistical signiﬁ-
cance of differences was assessed by using the Statistical Packagefor the Social Sciences (IBM-SPSS Inc IBM SPSS Statistics 21.0-
(2012.Aug), Armonk, New York). The data were analyzed using a 2-
tailed Student t test. The differences between the means were
considered signiﬁcant at P o 0.05.Results
Low-concentration rapamycin inhibited EOMA cell proliferation
in vitro
To analyze the effect of rapamycin on vascular tumor growth
in vitro, EOMA cells were incubated in different concentrations of
rapamycin. WST-1 cell proliferation assay were used to measure
cell proliferation. Quadruplicate cultures of EOMA cells were
grown overnight in complete medium with or without rapamycin.
Rapamycin inhibited proliferation of EOMA cells in a dose-
dependent manner (Figure 1). A concentration 41 nM rapamycin
showed a signiﬁcant inhibition of the proliferation (0 nM vs 1, 5,
10, and 20 nM; P o 0.01). These results showed that EOMA cells
have obvious sensitivity to rapamycin. Different concentrations of
rapamycin all played an important role in the inhibition of EOMA
cell proliferation (Figure 2). More signiﬁcantly, the low concen-
tration group, compared with controls, still showed signiﬁcant
inhibition with minimal side effects.
Low-concentration rapamycin inhibited EOMA cell migration in vitro
The ability of tumor cells to migrate is an important prereq-
uisite for tumor dissemination and metastasis. The ability of
rapamycin to inhibit the migration of EOMA cells toward VEGF
was measured using transwell migration assays. Forty-eight hour
low-dose rapamycin treatment showed a signiﬁcantly strong
inhibitory effect on EOMA cells. These antimigratory effects of
rapamycin were also dose-dependent (Figures 3 and 4)
(P o 0.01).
Low-concentration rapamycin inhibited vascular tumor growth
in vivo
The effect of rapamycin on vascular tumor growth in vivo was
tested next. We used xenograft mouse models with EOMA cells
injected subcutaneously in the ﬂank of mice. Mice of the control
group were given normal saline by intraperitoneal injection,
whereas those of the rapamycin test group were given a dose of
Control Rapamycin (10nM)
20µM
Figure 2. Single-layer hemangioendothelioma endothelial (EOMA) cells observed
under microscopy (20 ) with rapamycin treatment for 48 hours. Rapamycin (10
nM) inhibited EOMA cell proliferation compared with control.
Control Rapamycin (10nM)
20 μM
Figure 4. Migrated hemangioendothelioma endothelial (EOMA) cells with rapa-
mycin treatment for 48 hours under inverted microscope (200). Rapamycin (10
nM) inhibited EOMA cell migration compared with control.
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volume of vascular tumor was measured from Day 0 to Day 12.
Compared with the control group, vascular tumor size in the
rapamycin test group (0.5 mg/kg) was much smaller from Day 6 to
Day 12. This low dose of rapamycin blocked vascular tumor growth
signiﬁcantly (Figure 5) (P o 0.05). The mice in the highest dose
cohort died.
Rapamycin inhibited phosphorylation of the AKT/mTOR/S6 signaling
pathway
We next examined whether AKT/mTOR/S6 signaling activation
was also inhibited and attempted to ﬁnd the probable mechanism
by which rapamycin inhibits hemangioma endothelial cell prolif-
eration, migration, and vascular tumor formation. In the experi-
ments above, 10 nM rapamycin showed obvious inhibitory effect
on proliferation, migration, and vascular tumor growth in EOMA
cells. Here, EOMA cells were treated with 10 nM rapamycin for 48
hours. EOMA cells of the starvation group were treated with
DMEM medium with only 0.1% FBS. EOMA cells of the serum
group were treated with full DMEM with 10% FBS. Western blot
analysis showed that phosphorylation of AKT (Ser473), mTOR,
GSK3β, and S6 were all hyperactivated in the serum group, but
markedly decreased by rapamycin treatment with α-tubulin as
protein loading control (Figure 6).0.5
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Figure 3. Low concentrations of rapamycin treatment affected cell migration (n¼
5 in each group). Rapamycin (1–20 nM) inhibited hemangioendothelioma endothe-
lial cell migration compared with control (P o0.05).life-threatening consequences.11 Hemangioma is implicated in a
wide spectrum of clinical diseases, ranging from common heman-
gioma in children to malignant angiosarcoma in adults.12 Vascular
tumor malformations have been found in some genetic syn-
dromes, like posterior fossa malformations–hemangiomas–arterial
anomalies–cardiac defects–eye abnormalities–sternal cleft and
supraumbilical raphe syndrome, Kasabach-Merritt syndrome,
Sturge-Weber syndrome, and Klippel-Trenaunay syndrome.1,13,14
Treatment options include laser ablation, surgical resection, and
medication. Drugs such as propranolol, interferons, and cortico-
steroids are commonly used.15,16 However the efﬁcacy and risks of
these drugs are still under investigation due to varying severity of
the side effects, including the possible risk of interferon causing
neurologic problems in children.
Rapamycin is a bacterial macrolide previously identiﬁed as an
antifungal agent. It is also an effective AKT inhibitor in vascular
endothelial cells.17,18 It inhibits target of rapamycin (TOR) proteins,
a highly conserved group of serine/threonine kinases.15 mTOR0.2
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Figure 5. Rapamycin treatment affected tumor growth in Nu/Nu mice. heman-
gioendothelioma endothelial cells were injected subcutaneously in the ﬂank of
mice (5 mice per group). Rapamycin (0.5 mg/kg, 1 mg/kg, 1.5 mg/kg, and 2 mg/kg)
or vehicle was injected daily, intraperitoneally. Tumor size was monitored for 12
days. Low concentration of rapamycin (0.5 mg/kg) signiﬁcantly reduced tumor
growth compared with control from Day 6 to Day 12 (P o 0.05). The mice in the
highest-dose group ( 2 mg/kg) died.
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Figure 6. Western blot analysis of rapamycin treatment in hemangioendothelioma
endothelial cells for protein kinase B (AKT)/mammalian target of rapamycin
(mTOR) signaling pathway. Decreased phosphorylations of mTOR, AKTSer473,
glycogen synthase kinase-3 beta (GSK3β), and S6 occurred with α-tubulin as
protein loading control. ST ¼ starvation group treated with Dulbecco’s modiﬁed
Eagle’s medium with only 0.1% fetal bovine serum; SE ¼ serum group treated with
full Dulbecco’s modiﬁed Eagle’s medium with 10% fetal bovine serum; Rapa ¼ 10
nM rapamycin for 48 hours.
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which controls ribosomal biogenesis, and eukaryotic initiation
factor 4E-binding protein 1, which regulates mRNA translation.
mTOR is essential to the accumulation of cell mass (growth) and
increase in cell number (proliferation).19 Rapamycin regulates the
growth of endothelial cells by inhibiting mTOR complex.18 Thus, it
can be seen that hemangioma accompanied by excessive AKT
activation should be particularly sensitive to rapamycin.20
Clinically, rapamycin is used as an immunosuppressant for solid-
organ transplant recipients and in cardiovascular stents to prevent
postangioplasty restenosis, but recent attention has been focused on
the potential of rapamycin for treating cancer.5–7 The Phase I and II
studies with rapamycin analogs in breast and other cancers have
demonstrated favorable responses.20 Rapamycin also can target the
self-renewal and vascular differentiation potential in patient-derived
hemangioma stem cells.21 Despite the potential of rapamycin for
tumor treatment, its effect on hemangioma has not yet been
investigated. In fact, we indeed observed that rapamycin signiﬁcantly
inhibited the proliferation and migration of mouse EOMA cells
in vitro and vascular tumor growth in vivo. We also demonstrated
that phosphaidylinositol 3-kinase/AKT/mTOR/S6 kinase signaling
pathways are involved in rapamycin inhibiting the endothelial cell
proliferation and migration process. AKT represents an important
upstream molecule of the mTOR pathway. mTOR has 2 kinds of
complexes, mTOR complex 1 (mTOR1) and mTOR complex 2
(mTOR2). AKT phosphorylation at Ser473 is activated by mTOR2
and associate with resistance to apoptosis, increased cell growth, cell
proliferation, and cell energy metabolism. Studies have shown that
the inhibition of mTOR1 and mTOR2 caused by rapamycin is time
and cell type dependent.22 mTOR contributes to hemangioma
endothelial cell proliferation by stimulating an autocrine loop of
VEGF signaling.23,24 In our study, long-time treatment with rapamy-
cin inhibited both mTOR1 and mTOR2 in EOMA cells. Strong
inhibition of mTOR2 phosphorylation induced the hypoactivation of
phospho-AKT at Ser473 after 48-hour rapamycin treatment. GSK3β, a
downstream kinase of AKT, implicated in the regulation of cell
proliferation and apoptosis, was downregulated here. S6, involved
in the regulation of cell size and proliferation, was also inhibited
signiﬁcantly. So the suppression of vascular tumor results from the
inhibition of both mTOR1 and mTOR2 caused by rapamycin in
vascular endothelial cells. Furthermore, with the increasing impor-
tance of drug-dose effects, it is worthwhile to pursue research on
low-concentration rapamycin induced suppression of hemangioma.
It is already evident that rapamycin has some severe adverse
reactions such as immunosuppression, hyperlipidemia, liver damage,bone marrow suppression, and thrombocytopenia.25 How to
decrease the dose and keep the curative effect is the most critical
point. The serum concentration of rapamycin in clinical application is
usually within 7 to 16 nM.26 In our study the concentration of
rapamycin used in vitro was analogous to low serum concentration.
In the study of in vivo 0.5 mg/kg rapamycin injected intraperitoneally
in mice (about 10 g) was amount to 17.3 mg/kg relative to the dose of
oral rapamycin in human beings by correcting for the route of
administration, the free fraction, and the frequency of administration
differences between mouse and man. It is calculated by the formula
of kilogram IP dose in mouse coefﬁcient of the same route of
administration: (387.9) / 14% / bioavailability of IP (80%). So 0.5 mg/kg
rapamycin was low dose relative to the dose of oral rapamycin (16–
24 mg/kg).27 Under the condition of low drug concentration, rapa-
mycin also signiﬁcantly inhibited the growth of hemangioma. These
results should provide a low toxicity and adverse reaction alternative
for the treatment of hemangioma compared with commonly used
drugs like propranolol, interferons, and corticosteroids. In addition,
we also tried to detect the dose-related efﬁcacy and the safe dose
range of rapamycin treatment. The mice with 2 mg/kg rapamycin
injection in vivo died during the beginning days. This suggested a
narrow and not very wide therapeutic index drug treatment. It
encourages continued development of rapamycin and its analogs
for use to increase the LD50 and therapeutic index in vascular tumor
therapy in future research.Acknowledgments
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